1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 11, 2019--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, yesterday gave back to the communities where Alnylam employees live and work at its fifth annual company-wide “Helping Hands” Community Service Day.
The program has successfully expanded to include 1,000 employees, volunteering across 40 organizations globally, dedicating more than 4,000 hours to local causes and organizations. This year, for the first time, Alnylam employees who work remotely were provided the opportunity to volunteer in the local communities where they live.
“Each year we look forward to our ‘Helping Hands’ Community Service Day. The concept of giving back is foundational to Alnylam, and the energy and enthusiasm our employees bring to these worthy organizations across the globe is palpable,” said John Maraganore, Chief Executive Officer of Alnylam. “We are extremely grateful to both our new partners and the organizations who continue to welcome us back year after year.”
Activities range from supporting underserved youth, restoration of parks, home ownership for low income families, fighting hunger, and other neighborhood initiatives. Beneficiary organizations include:
Food Pantries and Meal Services
Childcare and Community Programs
The Company’s employees in Munich, Germany and Amsterdam, Netherlands held their Community Service Day earlier this summer. In addition, employees in Zug, Switzerland; Paris, France; Milan, Italy; and Stockholm, Sweden will volunteer at local organizations later this Fall.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of diseases with high unmet need. Alnylam’s first commercial RNAi therapeutic is ONPATTRO ® (patisiran), approved in the U.S., EU, Canada, and Japan. Alnylam has a deep pipeline of investigational medicines, including five product candidates in Phase 3 studies and one in registration. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Headquartered in Cambridge, MA, Alnylam employs over 1,200 people worldwide. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190911005429/en/
CONTACT: Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: OTHER PHILANTHROPY BIOTECHNOLOGY PHARMACEUTICAL HEALTH GENERAL HEALTH PHILANTHROPY
SOURCE: Alnylam Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 09/11/2019 08:30 AM/DISC: 09/11/2019 08:30 AM